Pay in 4 interest-free payments of $6.27 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
Dig Dis Sci 40: 1074-1082, 1995
In one of the largest trials of a GLP-1 tablet for weight loss, 667 participants adults with obesity or overweight (without diabetes) were observed
Mostly delivered via subcutaneous injection shot, GLP-1 agonist medications mimic this hormones role in the body
A: According to published clinical trial data for FDA-approved medications: Wegovy (semaglutide 2.4 mg): Average 15% body weight loss at 68 weeks (approximately 33 pounds for 220-pound individual) Zepbound (tirzepatide 15 mg): Average 20% body weight loss at 72 weeks (approximately 44 pounds for 220-pound individual) Critical Context : These represent average results from controlled clinical trials where participants also followed reduced-calorie diets and increased physical activity
US$ 26.87
US$ 29.37
US$ 27.99
US$ 22.56
US$ 25.84
US$ 27.23
